KLRS: Kalaris Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-10-26 | New 13G stake | Coastlands Capital LP | 5.69% | SEC |
Institutional ownership (Q2 2026)
56 institutions reported holding $73.29M of Kalaris Therapeutics, Inc. on Form 13F (58 the quarter before). 9 opened a new position and 11 sold out. Shares held by institutions: -4%.
| Largest holders | Shares | Value |
|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 12,881,175 | $52.43M |
| RTW INVESTMENTS, LP | 1,300,000 | $5.29M |
| Alyeska Investment Group, L.P. | 572,687 | $2.33M |
| Siren, L.L.C. | 435,798 | $1.77M |
| VANGUARD CAPITAL MANAGEMENT LLC | 398,712 | $1.62M |
| Ikarian Capital, LLC | 360,000 | $1.47M |
| UBS Group AG | 262,131 | $1.07M |
| RENAISSANCE TECHNOLOGIES LLC | 149,351 | $608K |
| MARSHALL WACE, LLP | 139,201 | $567K |
| GEODE CAPITAL MANAGEMENT, LLC | 114,037 | $464K |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.